11:24 AM EST, 11/11/2025 (MT Newswires) -- Surgery Partners ( SGRY ) is still tracking toward the midpoint of its 4% to 6% same-store revenue growth guidance in 2025, even as softening commercial volume is "concerning," RBC Capital Markets said in a note emailed Tuesday.

While the company does not assume the volume and commercial mix headwinds will continue in the longer term, it is monitoring for potential implications for its 2026 plans, RBC said.

With Surgery Partners ( SGRY ) lowering its 2025 guidance range, RBC said it was not "overly concerned" by the guide-down, especially with an active pipeline of opportunities into next year and organic growth still tracking to the midpoint of the company's long-term target.

The firm maintained its outperform rating on the company and lowered its price target to $31 from $35.

Price: 16.41, Change: +0.38, Percent Change: +2.34